Relative Biologic Effects of Low-Dose-Rate α-Emitting 227Th-Rituximab and β-Emitting 90Y-Tiuexetan-Ibritumomab Versus External Beam X-Radiation

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 1, 2008, Pages 186-192

  Dahle, Jostein ^a   Bruland, Øyvind S ^b   Larsen, Roy H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Alpha radiation; Beta radiation; Radioimmunotherapy; Relative biologic effect; Thorium 227

Indexed keywords

ALPHA-RADIATION; BETA-RADIATION; LOW DOSE RATES; PARTICLE RADIATION; RADIOIMMUNOTHERAPY; RELATIVE BIOLOGIC EFFECT; THORIUM-227;

RADIATION EFFECTS;

IBRITUMOMAB TIUXETAN; RADIOPHARMACEUTICAL AGENT; RITUXIMAB TH 227; TRASTUZUMAB TH 227; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA RADIATION; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; RAJI CELL; TUMOR XENOGRAFT;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; BETA RAYS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HALF-LIFE; IMMUNOCONJUGATES; LYMPHOMA, B-CELL; MICE; MICE, INBRED C3H; MICE, NUDE; RADIOIMMUNOTHERAPY; RELATIVE BIOLOGICAL EFFECTIVENESS; THORIUM; TRANSPLANTATION, HETEROLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 49749151055     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.05.029     Document Type: Article

References (21)

1. Henriksen G., Bruland O.S., and Larsen R.H. Thorium and actinium polyphosphonate compounds as bone-seeking α particle-emitting agents. Anticancer Res 24 (2004) 101-105
2. Nilsson S., Larsen R.H., Fossa S.D., et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11 (2005) 4451-4459
3. Nilsson S., Franzen L., Parker C., et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8 (2007) 587-594
4. Aurlien E., Larsen R.H., Akabani G., et al. Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: Analysis of cell survival and microdosimetry. Int J Radiat Biol 76 (2000) 1129-1141
5. 213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 61 (2001) 2008-2014
6. Barendsen G.W. RBE-LET relationships for different types of lethal radiation damage in mammalian cells: Comparison with DNA dsb and an interpretation of differences in radiosensitivity. Int J Radiat Biol 66 (1994) 433-436
7. 210Po alpha-particles versus X-rays on lethality in bovine endothelial cells. Int J Radiat Biol 79 (2003) 107-118
8. 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: Relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging 30 (2003) 1357-1364
9. Behr T.M., Behe M., and Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: Empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm 17 (2002) 445-464
10. 60Co irradiation in nude mice. J Nucl Med 46 (2005) 464-471
11. Howell R.W., Azure M.T., Narra V.R., and Rao D.V. Relative biological effectiveness of α-particle emitters in vivo at low doses. Radiat Res 137 (1994) 352-360
12. Howell R.W., Goddu S.M., Narra V.R., et al. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: Relative biological effectiveness of α-particle emitters in vivo. Radiat Res 147 (1997) 342-348
13. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an α-emitter in vivo. J Nucl Med 46 (2005) 2061-2067
14. Dahle J., Borrebaek J., Jonasdottir T.J., et al. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood 110 (2007) 2049-2056
15. 227Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. Nucl Med Biol 33 (2006) 271-279
16. 227Th-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. Cancer Biother Radiopharm 22 (2007) 431-437
17. Lindmo T., and Bunn Jr. P.A. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol 121 (1986) 678-691
18. Institute for Transuranium Elements, Karlsruhe, Germany. Nuclide Explorer 2000 [computer program]. Joint Research Centre of the European Commission, 2000.
19. 177Lu radionuclides. Cancer Biother Radiopharm 20 (2005) 436-449
20. Hall E.J. Radiobiology for the radiologist (2000), Lippincott Williams & Wilkins, Philadelphia
21. Miederer M., McDevitt M.R., Sgouros G., et al. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med 45 (2004) 129-137